<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045043</url>
  </required_header>
  <id_info>
    <org_study_id>GRADE</org_study_id>
    <secondary_id>R01HL077398</secondary_id>
    <nct_id>NCT02045043</nct_id>
  </id_info>
  <brief_title>Genetic Risk Assessment of Defibrillator Events</brief_title>
  <acronym>GRADE</acronym>
  <official_title>Genetic Risk Assessment of Defibrillator Events: A Prospective Multicenter Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arrhythmias remain a major health problem, causing at least 250,000 deaths annually in the
      United States. Pharmacological treatments often do more harm than good, and device therapies
      are limited by high cost and effects on quality of life. Ion channel mutations cause rare
      inherited arrhythmopathies, but account for only a small fraction of patients with life-
      threatening arrhythmias and sudden death. Most arrhythmias occur during myocardial ischemia,
      following myocardial infarction, and in patients with poor left ventricular (LV) function of
      any etiology. Aside from ejection fraction (EF), few clinically useful indicators to stratify
      the risk of sudden death have been identified. The role of subtle difference in ion channel
      expression and/or structure in predisposing patients to arrhythmias and modulating the risk
      of sudden death is unknown.

      In this study, we are prospectively testing whether polymorphisms in ion channels and ion
      channel modifying genes are associated with arrhythmias in a population with internal
      cardioverter-defibrillators (ICDs) and poor LV function. We will test the hypothesis that
      functional polymorphisms in the coding sequences and promoter regions of cardiac genes (e.g.
      ion channels, beta-adrenergic receptors) predispose individuals to arrhythmias and /or heart
      failure progression.

      We hope to identify genetic predictors for the common forms of sudden cardiac death. This
      would allow the identification of a subpopulation of heart failure patients that would
      benefit most from ICD placement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Shock-Free Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time to first appropriate shock from an Implantable Cardioverter-Defibrillator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant- and VAD-Free Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time to occurence of death from any cause, cardiac transplantation, or Ventricular Assist Device placement (whichever comes first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate Shock Frequency</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The number of appropriate shocks per year</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1807</enrollment>
  <condition>Sudden Cardiac Death</condition>
  <condition>Arrhythmias</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Cardiomyopathy patients with ICDs</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood was obtained for DNA (all subjects) and serum (subgroup of subjects)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects 18 years of age and over with a cardiomyopathy, an ejection fraction less than or
        equal to 30%, and an implantable cardioverter defibrillator
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An ICD placed during the last 5 years, or a planned ICD within 1 month

          -  Age 18 or older

          -  Left Ventricular Ejection fraction &lt; or = 30%

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Patient refuses or is unable to give consent

          -  A life expectancy &lt;6 months from a non-cardiac life threatening disease

          -  Ongoing Class IV heart failure symptoms despite treatment

          -  History of cardiac transplant or left ventricular assist device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry London, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massuchetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Cardiology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Refaat MM, Lubitz SA, Makino S, Islam Z, Frangiskakis JM, Mehdi H, Gutmann R, Zhang ML, Bloom HL, MacRae CA, Dudley SC, Shalaby AA, Weiss R, McNamara DM, London B, Ellinor PT. Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy. Heart Rhythm. 2012 Mar;9(3):390-6. doi: 10.1016/j.hrthm.2011.10.016. Epub 2011 Oct 17.</citation>
    <PMID>22004663</PMID>
  </reference>
  <results_reference>
    <citation>Blanco RR, Austin H, Vest RN 3rd, Valadri R, Li W, Lassegue B, Song Q, London B, Dudley SC, Bloom HL, Searles CD, Zafari AM. Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure. J Card Fail. 2012 Sep;18(9):717-23. doi: 10.1016/j.cardfail.2012.06.531. Epub 2012 Aug 9.</citation>
    <PMID>22939041</PMID>
  </results_reference>
  <results_reference>
    <citation>Bloom HL, Shukrullah I, Veledar E, Gutmann R, London B, Dudley SC. Statins Decrease Oxidative Stress and ICD Therapies. Cardiol Res Pract. 2010;2010:253803. doi: 10.4061/2010/253803. Epub 2010 Mar 25.</citation>
    <PMID>20369058</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Barry London</investigator_full_name>
    <investigator_title>Director, Division of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>Sudden Cardiac Death</keyword>
  <keyword>Arrhythmias</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Single Nucleotide Polymorphisms</keyword>
  <keyword>Genomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

